首页|ELOVL3在预测肝细胞癌预后中的作用

ELOVL3在预测肝细胞癌预后中的作用

扫码查看
目的 探索精准预测肝细胞癌患者预后的分子标志物.方法 在TCGA数据库下载肝细胞癌(LIHC)样本的mRNA表达数据及相应的临床预后数据,并且收集从2017年1月1日至2022年1月1日在新疆维吾尔自治区人民医院接受肝切除手术的91例肝细胞癌(HCC)患者的临床病理资料和随访资料.用R软件筛查差异表达基因(DEGs)后,进一步进行Cox单变量回归分析和LASSO回归分析筛出与HCC患者生存相关的风险基因;用R软件的ggplot2分析包和免疫组织化学染色法分析ELOVL3在不同肝组织上的表达情况,Survival分析包实现Kaplan-Meier生存分析.结果 初步筛查得到752个DEGs,包括表达上调的247个基因和505个下调基因.进一步通过Cox回归分析得出175个与HCC患者的生存显著相关的基因集,LASSO回归分析,挑出14个与HCC患者生存密切相关的风险基因.最终通过预实验和文献调研将目标基因确定为ELOVL3.TCGA-LIHC的分析结果显示:ELOVL3在癌组织中的表达量明显高于正常肝组织(P<0.001),而且该基因在癌组织中的表达量也高于互相匹配的癌旁组织(P<0.001).免疫组化染色结果提示:ELOVL3在59例(64.8%)患者的肝癌组织中表达阳性,而32例(35.2%)患者的肝癌组织中没有表达;在互相匹配的癌旁组织中表达均为阴性.生存分析结果显示ELOVL3阳性患者的5年生存率明显比ELOVL3阴性患者低(r=0.028);ELOVL3高表达的患者总体生存率相对于ELOVL3低表达的患者低,而且表达量越高,预后越差(HR=1.7,P=0.008).结论 ELOVL3的表达与HCC患者的不良预后相关,而且具有做预测HCC预后的新型分子标志物的潜力.
Role of ELOVL3 in predicting the prognosis of hepatocellular carcinoma
Objective To explore molecular markers to accurately predict the prognosis of patients with hepatocellular carcinoma.Methods The TCGA database was accessed to obtain the mRNA expression data and associated clinical prog-nosis data of hepatocellular carcinoma(LIHC)samples.Additionally,clinicopathological and follow-up data were collected from 91 patients diagnosed with hepatocellular carcinoma(HCC)who underwent hepatectomy at the Xinjiang Uygur Au-tonomous Region People's Hospital between January 1,2017,and January 1,2022.Following a screening of differentially expressed genes(DEGs)using R software,risk genes linked to the survival of HCC patients were further screened using Cox univariate regression analysis and LASSO regression analysis;the expression of ELOVL3 in various liver tissues was analyzed using the ggplot2 analysis package and immunohistochemical staining;Kaplan-Meier survival analysis was real-ized using the survival analysis package.Results Total 752DEGs were obtained,including of 247 upregulated genes and 505 down-regulated genes.Coxunivariate regression analysis was used to identify 175 genes from DEGs that were signifi-cantly associated with survival of HCC patients,and 14 risk genes that were closely related to the survival of HCC patients were further selected by LASSO regression analysis.The ggplot2 tool in R provided analysis findings that demonstrated ELOVL3 expression levels in tumor tissues were significantly greater than those in normal tissues(P<0.001)and also higher than those in matching para-tumor tissues(P<0.001).Immunohistochemical staining results revealed that 32 pa-tients(35.2%)did not have positive ELOVL3 results,while 59 patients(64.8%)did.They were negative in matched ad-jacent tissues.According to survival analysis,patients who tested positive for ELOVL3 had a significantly lower 5-year survival rate(r=0.028)than patients who tested negative for ELOVL3;additionally,patients who expressed high levels of ELOVL3 had a lower overall survival rate than those who expressed low levels of the protein,and their prognosis worsened with higher expression levels(HR=1.7,P=0.008).Conclusion It is anticipated that ELOVL3 will serve as a unique molecular marker for predicting the outcome of HCC.

Hepatocellular carcinomaTCGA data baseDifferentially expressed genesPrognosis

宁娜、巴图、穆尼沙·买买提力、玉苏甫卡迪尔·麦麦提尼加提、卢爽、陈雄

展开 >

新疆维吾尔自治区人民医院肝胆外科,乌鲁木齐 830011

新疆维吾尔自治区人民医院病理科,乌鲁木齐 830011

新疆第二医学院临床医学院,克拉玛依 834000

肝细胞癌 TCGA数据库 差异表达基因 预后

新疆维吾尔自治区自然科学基金项目新疆维吾尔自治区人民医院院内项目

2023D01C22520210207

2024

诊断病理学杂志
北京军区总医院

诊断病理学杂志

CSTPCD
影响因子:0.663
ISSN:1007-8096
年,卷(期):2024.31(8)